Clinical Trials Logo

Insulin Resistance clinical trials

View clinical trials related to Insulin Resistance.

Filter by:

NCT ID: NCT03178396 Completed - Healthy Clinical Trials

Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets

Start date: December 7, 2015
Phase: N/A
Study type: Interventional

The investigators will be studying the effect of melatonin on blood pressure, insulin resistance, and platelets, along with possible reasons for how melatonin cases these effects.

NCT ID: NCT03167996 Completed - Hypertension Clinical Trials

Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology

HealthPals
Start date: June 23, 2016
Phase: N/A
Study type: Interventional

This platform will enable investigation the cardiovascular risk reduction and the increase in participant engagement in their heart-healthy goals, through the use of virtual care/telemedicine with a digital platform that connects them to their own doctors, nurses, and dietitians.

NCT ID: NCT03159065 Completed - Clinical trials for Postprandial Hyperglycemia

Postprandial Efficacy of Probiotic Fruit Beverages on Glucose Tolerance and Insulin Resistance

Start date: September 2014
Phase: N/A
Study type: Interventional

Consumption of polyphenol-rich fruits and vegetables may improve the postprandial glucose and insulin responses and hence promote well-being. It has previously been observed that consumption of a bilberry drink decreases the postprandial insulin demand. In the present study, the impact of probiotic fruit beverages with different polyphenol profiles on the postprandial levels of glucose and insulin, were investigated.

NCT ID: NCT03146286 Completed - Insulin Resistance Clinical Trials

Skeletal Muscle Protein Metabolism and Insulin Sensitivity in Overweight Individuals: Effects of Meals With Various Fatty Acid Compositions

Start date: August 1, 2015
Phase: N/A
Study type: Interventional

The aim of the study will investigate whether impairment in the action of insulin to promote the use of glucose in skeletal muscle (insulin resistance) as a result of oral ingestion of a liquid meal rich in saturated fat is linked to reduced ability of muscles to synthesise new protein in response to dietary protein intake, which ultimately may compromise maintenance of muscle size and quality of life and whether partially replacing saturated fat in the liquid meal with omega 3 polyunsaturated FA (n3PUFA) will ameliorate these negative effects.

NCT ID: NCT03142633 Completed - Insulin Resistance Clinical Trials

MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome

Start date: September 9, 2016
Phase:
Study type: Observational

The aim of this study is to explore the microRNA profile in serum of women with Polycystic Ovary Syndrome and investigate the correlation between the microRNA profile and markers of metabolic syndrome.

NCT ID: NCT03138746 Completed - Insulin Resistance Clinical Trials

Insulin Sensitivity During Hyperbaric Oxygen Compared to Hyperbaric Air

HOTAIR4
Start date: August 13, 2018
Phase:
Study type: Observational

In a recent series of studies performed by our group, we have shown that exposure to hyperbaric oxygen (HBO) leads to an increase in insulin sensitivity in male subjects with type-2 diabetes (T2DM) and in obese and overweight men without diabetes. The aim of this study is to investigate the relationship between pressure and oxygen in producing this effect, specifically, is this effect measurable in hyperbaric air or is some higher pressure of oxygen required? Aims: 1. To determine whether the insulin sensitising effect of HBO is apparent in hyperbaric air at the same pressure as HBO. 2. To examine mechanisms underpinning the increase in insulin sensitivity following HBO.

NCT ID: NCT03135015 Completed - Clinical trials for Insulin Resistance, Diabetes

Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans

Start date: April 26, 2017
Phase: Phase 1
Study type: Interventional

Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose (blood sugar) which is absorbed from the intestine into the blood leading to a rise in glucose which triggers the secretion of insulin. Insulin binds to cells in the liver, muscle and fat, triggering them to take up glucose and bring the blood glucose level back to normal. A high blood sugar level is known as diabetes. The most common form of diabetes, type 2 diabetes, is caused by insulin resistance; that is, a reduced ability of insulin to stimulate glucose uptake into cells. The body compensates for insulin resistance by making more insulin; type 2 diabetes occurs when the pancreas can no longer make enough insulin to control blood glucose. The high blood glucose and insulin levels lead to long-term complications such as heart attacks, kidney failure, reduced sensation and poor circulation in the feet and legs. Reducing blood glucose levels with oral medications and insulin reduces risk of diabetic complications. There are several types of oral medications available for treating diabetes; however, they do not always control blood glucose adequately. In addition, these drugs have complications and are not used to treat insulin resistance and prediabetes - a condition when blood glucose is higher than normal but not high enough to be classified as diabetes. Prediabetes often progresses to diabetes over a period of months or years. Effective and safe treatments for prediabetes could prevent or delay the onset of diabetes. Axulin is a natural health product consisting of a mixture of extracts - derived from herbs and vegetables present in normal diets - which has been shown in cell culture and in animal studies to increase the ability of insulin to stimulate glucose uptake into cells. The active ingredient in Axulin is a botanical extract designated HP-211. Thus, HP-211 may reduce the blood glucose and insulin levels of subjects without diabetes after eating. HP-211 may also reduce glucose and insulin responses to a larger extent in insulin-resistant as compared to insulin-sensitive subjects. Subjects will take 0g, 2g, or 4g of capsules or tablets in the morning after an overnight fast; 40 minutes later they will consume 75g glucose dissolved in 300ml water. Blood glucose, insulin and fats will be measured before and for 2 hours after the glucose drink.

NCT ID: NCT03126981 Completed - PreDiabetes Clinical Trials

Effects of Almonds on Insulin Sensitivity in Prediabetes

Start date: April 20, 2017
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effects of consuming 1.5 oz almonds twice daily on insulin sensitivity and markers of cardiometabolic health in men and women with prediabetes.

NCT ID: NCT03120871 Completed - Obesity Clinical Trials

Microbiome Insulin Sensitivity Study

MISS
Start date: May 12, 2017
Phase:
Study type: Observational

The Microbiome Insulin Sensitivity Study "MISS" is a pilot study designed to study microbiome composition across puberty and how it relates to insulin sensitivity and secretion in obese girls, who are at increased risk for developing type 2 diabetes in puberty. The investigators will evaluate the gut microbiome composition in fecal samples of 57 obese girls in three groups: prepubertal (Tanner 1), early pubertal (Tanner 2-3), and late pubertal (Tanner 4-5). Insulin sensitivity will also be measured via an intravenous glucose tolerance test (IVGTT) in 18 prepubertal and late pubertal participants.

NCT ID: NCT03118479 Terminated - Clinical trials for Hypogonadotropic Hypogonadism

Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)

Start date: May 2010
Phase: Phase 1
Study type: Interventional

The investigators are doing this research study to look at the relationship between testosterone (the main sex hormone in men) and insulin (the hormone that controls blood sugar levels) in men with Idiopathic Hypogonadotropic Hypogonadism (IHH). The investigators hypothesize that normalizing testosterone levels in men with IHH enhances insulin sensitivity, reduces visceral fat, increases lean body mass, and improves the lipid profile.